Ikarian Capital, LLC - Significant Ownership

Signature - Title
/s/ Neil Shahrestani - Neil Shahrestani, Sole Manager
Location
Dallas, TX
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Ikarian Capital, LLC.

Significant Ownership of Ikarian Capital, LLC

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
SPRBD Spruce Biosciences Inc. Common Stock, par value $0.0001 per share 21.6% $1.11M 121K Ikarian Capital, LLC Oct 6, 2025
TENX Tenax Therapeutics, Inc. Common Stock, $0.0001 par value per share 21.2% $5.81M 968K Ikarian Capital, LLC Sep 30, 2025
AVTX Avalo Therapeutics, Inc. Common Stock, $0.001 Par Value 9.99% $6.91M 1.19M Ikarian Capital, LLC Mar 31, 2025
TRAW Traws Pharma, Inc. Common stock, par value $.01 per share 9.99% $1.16M $385K 590K +49.5% Ikarian Capital, LLC Mar 31, 2025
GRTX Galera Therapeutics, Inc. Common Stock, $0.001 par value per share 9.99% $377K 7.54M Ikarian Capital, LLC Dec 31, 2024
AEMD Aethlon Medical, Inc. Common Stock, $0.001 par value per share 8.7% $443K 1.23M Ikarian Capital, LLC Dec 31, 2024
CHRO Channel Therapeutics Corp Common Stock, par value $0.0001 per share 7.3% $595K 441K Ikarian Capital, LLC Dec 31, 2024
ATXI Avenue Therapeutics, Inc. Common Stock 6.8% $46.2K 140K Ikarian Capital, LLC Dec 31, 2024
ACOG Alpha Cognition Inc. Common Shares, no par value 6% $4.29M 968K Ikarian Capital, LLC Dec 31, 2024
FBRX Forte Biosciences, Inc. Common Stock, $0.001 par value 4.99% $7.06M $96.5K 618K +1.39% Ikarian Capital, LLC Jun 30, 2025
CPIX Cumberland Pharmaceuticals Inc. Common Stock, no par value 4.9% $3.09M 731K Ikarian Capital, LLC Mar 31, 2025

Schedules 13D/G Reported by Ikarian Capital, LLC:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Date Filed
* An asterisk sign (*) next to the price indicates that the price is likely invalid.